Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06855524 · ClinicalTrials.gov registry record · Phase 2
Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer
A Phase 2 study of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT06855524 is a Phase 2 study of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 34 participants, below the 402-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06855524, a Phase 2 study of Malignant Female Reproductive System Neoplasm and Malignant Digestive System Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial tests how well fucoidan works in preventing chemotherapy-related fatigue compared to a placebo in patients with gastrointestinal (GI) or gynecological (GYN) cancer. Fatigue poses a burden in patients with malignancies undergoing systemic chemotherapy. Fucoidan is a dietary supplement made of complex sugar that contain sulfate groups attached to their sugar units (sulfated polysaccharide) which found in brown seaweed. It is thought to have anti-inflammatory, anti-viral, anti-thrombotic, anti-diabetic, and anti-tumor effects in pre-clinical models. Giving fucoidan may be effective in preventing chemotherapy-related fatigue in patients with GI or GYN.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- DRUG Placebo Administration
- DIETARY_SUPPLEMENT Oligo-fucoidan
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06855524
The ClinicalTrials.gov registry entry for NCT06855524 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 402-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (92% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Malignant Female Reproductive System Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT06855524 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06855524 about?
NCT06855524 is a clinical study titled "Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer". This clinical trial tests how well fucoidan works in preventing chemotherapy-related fatigue compared to a placebo in patients with gastrointestinal (GI) or gynecological (GYN) cancer. Fatigue poses a burden in patients with malignancies undergoing systemic chemotherapy. Fucoidan is a dietary supple...
What is the current status of trial NCT06855524?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2025-03-06. Estimated completion is 2027-02-28.
What conditions does trial NCT06855524 study?
This clinical trial studies the following conditions: Malignant Female Reproductive System Neoplasm, Malignant Digestive System Neoplasm.
What interventions are being tested in trial NCT06855524?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Placebo Administration (DRUG), Oligo-fucoidan (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06855524?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06855524 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Female Reproductive System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
-
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RECRUITING · Phase 2
-
An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors
RECRUITING · NA
-
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
RECRUITING
-
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
RECRUITING · Phase 3
Explore more on PlainTrial
Malignant Female Reproductive System Neoplasm
All registered trials for this condition
Malignant Digestive System Neoplasm
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.